Literature DB >> 19207169

Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline.

M Cramer1, R Frei, A Sebald, P Mazzoletti, W Maeder.   

Abstract

BACKGROUND AND OBJECTIVES: IgPro10 (Privigen) is a new liquid intravenous immunoglobulin (IVIG) product that is formulated with 250 mM L-proline at pH 4.8. A 3-year study was performed to assess its stability.
MATERIALS AND METHODS: Physicochemical, biological and immunological parameters of Privigen were assessed during storage under controlled conditions over up to 36 months at 25 degrees C.
RESULTS: Privigen was shown to be stable after storage for 3 years at room temperature (25 degrees C). Of all parameters tested, only a few showed changes during storage. The appearance of the solution complied with the specifications given by the European Pharmacopeia over the full study period, with a single exception. The IgG fraction in Privigen displayed high purity (> or = 98%), which did not change during storage over 36 months. No relevant amounts of aggregated IgG molecules were formed in Privigen samples and the ratio between monomers and dimers shifted slightly towards the equilibrium over time. Testing of reference antibody contents and the Fc function demonstrated that the biological activity and effector functions of Privigen were preserved over the full study period of 36 months.
CONCLUSION: Thirty-six months room temperature stability of Privigen was achieved at pH 4.8 with an innovative formulation containing the physiological stabilizer L-proline.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19207169     DOI: 10.1111/j.1423-0410.2008.01143.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  8 in total

1.  Privigen immune globulin intravenous (human), 10% liquid.

Authors: 
Journal:  P T       Date:  2011-08

2.  Reconstituted human polyclonal plasma-derived secretory-like IgM and IgA maintain the barrier function of epithelial cells infected with an enteropathogen.

Authors:  Stéphanie Longet; Cédric Vonarburg; Marius Lötscher; Sylvia Miescher; Adrian Zuercher; Blaise Corthésy
Journal:  J Biol Chem       Date:  2014-06-20       Impact factor: 5.157

3.  Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates.

Authors:  John W Sleasman; Carla M Duff; Theresa Dunaway; Mikhail A Rojavin; Mark R Stein
Journal:  J Clin Immunol       Date:  2010-03-10       Impact factor: 8.317

4.  Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.

Authors:  Richard L Wasserman; Isaac Melamed; Robert P Nelson; Alan P Knutsen; Mary Beth Fasano; Mark R Stein; Mikhail A Rojavin; Joseph A Church
Journal:  Clin Pharmacokinet       Date:  2011-06       Impact factor: 6.447

5.  Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies.

Authors:  Stéphanie Longet; Sarah Miled; Marius Lötscher; Sylvia M Miescher; Adrian W Zuercher; Blaise Corthésy
Journal:  J Biol Chem       Date:  2012-12-18       Impact factor: 5.157

6.  Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.

Authors:  Brigitte Siani; Katharina Willimann; Sandra Wymann; Adriano A Marques; Eleonora Widmer
Journal:  Biol Ther       Date:  2014-05-20

7.  Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.

Authors:  Morna J Dorsey; Viet Ho; Mohsen Mabudian; Pere Soler-Palacín; Nerea Domínguez-Pinilla; Radha Rishi; Rahul Rishi; Duane Wong; Mikhail Rojavin; Alphonse Hubsch; Melvin Berger
Journal:  J Clin Immunol       Date:  2014-07-01       Impact factor: 8.317

8.  Plasma-Derived Polyreactive Secretory-Like IgA and IgM Opsonizing Salmonella enterica Typhimurium Reduces Invasion and Gut Tissue Inflammation through Agglutination.

Authors:  Gilles Bioley; Justine Monnerat; Marius Lötscher; Cédric Vonarburg; Adrian Zuercher; Blaise Corthésy
Journal:  Front Immunol       Date:  2017-08-29       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.